Natriuretic Peptides in Cardiac Anesthesia and Intensive Care

• Published in: Journal of cardiothoracic and vascular anesthesia 2019-05, Vol.33 (5), p.1407-1419
• Main Authors: Krichevskiy, Lev A., Kozlov, Igor A.
• Format: Article
• Language: English
• Subjects: cardiac anesthesia; cardiac surgery; intensive care; natriuretic peptides
• ISSN: 1053-0770; 1532-8422
• DOI: 10.1053/j.jvca.2018.08.019

Natriuretic peptides, predominantly B-type, are widely used in cardiology as prognostic and diagnostic biomarkers or, much less often, as a substantive treatment tool. They are hormones that are produced mainly in the myocardium in response to overload and ischemia, and their level quite accurately reflects the degree of myocardial dysfunction. Although their use in cardiac anesthesia and intensive care setting seems to be very beneficial for assessing the risk of acute disturbance of myocardial function or its laboratory monitoring, the actual significance of natriuretic peptides in this area is not yet recognized. This is due to the lack of clear diagnostic and prognostic values for these biomarkers supported by high-quality researches. On the basis of the available data, main advantages, existing difficulties, and most effective ways of using natriuretic peptides for determining the risk of heart surgery and assessing the severity of sepsis, pneumonia, and other critical conditions have been discussed in this review. In addition, the expediency of using natriuretic peptides as target parameters for goal-oriented therapy and as a substantive tool for treatment is considered.